Understanding why Mutations Matter in Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis) with Dr. Alexander Coltoff image

Understanding why Mutations Matter in Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis) with Dr. Alexander Coltoff

May 27, 2026
04:00PM - 05:00PM EDT
Online Event
Overview

Join the HealthTree Foundation for an in-depth exploration of how genetic profiles shape the landscape of Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis. Dr. Alexander Coltoff will guide us beyond the basic driver mutations to explain how "co-mutations" influence disease progression and long-term outlook. By understanding these complex genetic markers, you will gain the clarity needed to partner with your care team on more precise, personalized treatment decisions.

 

Agenda
4:00 PM
Introductions
Dalton Bean

Dalton introduces the agenda of the event and featured speaker with Dr. Alexander Coltoff 

4:05 PM
Presentation
Alexander Coltoff, M.D.

Dr. Coltoff talks about mutations affecting MPNs

4:35 PM
Questions and Answers
Audience

Come with your questions and will answer them! 

Speakers & Moderators
Healthtree contact Dalton Bean

Dalton Bean

Dalton joined HealthTree in 2024 as the CLL Education Manager.

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Healthtree contact Alexander Coltoff, M.D.

Alexander Coltoff, M.D.

Alexander Coltoff, M.D. received his medical degree from SUNY Downstate College of Medicine. He then completed his internal medicine residency at the Icahn School of Medicine at Mount Sinai, followed by a fellowship in Hematology/Oncology at New York Presbyterian - Columbia, both in New York. His clinical and research focus is on hematologic malignancies, particularly myeloproliferative neoplasms (MPNs), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). He has been published as a clinical investigator and received an American Society of Hematology (ASH) award for developing research scientists.